INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval

INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.

Feb 8, 2024 - 18:00

INCB-57643 is under clinical development by Incyte and currently in Phase II for Myelofibrosis.

Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts ...

AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

AF stroke patients could benefit from earlier anticoagulant administration

AF stroke patients could benefit from earlier anticoagu...

Oct 26, 2024

AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal

AstraZeneca to acquire radioconjugate biotech Fusion in...

Mar 20, 2024

Epigenetic drugs show 375% increase in Series A venture financing in 2024

Epigenetic drugs show 375% increase in Series A venture...

Sep 26, 2024